This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

Deep Track Capital disclosed a new 6.77 million-share stake in Alumis, with an estimated transaction value of $169.31 million and a quarter-end position value of $149.20 million. The buy represents 2.76% of Deep Track’s reportable AUM and signals constructive positioning in a late-stage biotech ahead of key lupus data and an NDA filing expected later this year. Alumis ended the quarter with $569.5 million in cash, funding operations into Q4 2027, but the stock’s sharp 355% one-year run leaves execution risk high.

Analysis

This is less a fundamental vote on the business than a signal that a specialist healthcare allocator is willing to tolerate binary clinical risk at scale. That matters because names like this tend to re-rate fastest when a credible owner shows up before the next data window; the marginal buyer is often not retail but crossover biotech capital that uses position-taking as a proxy for conviction ahead of readouts. The second-order effect is that the stock can become technically crowded into catalysts, which can amplify upside on good data but also create air pockets if expectations outrun the actual label or trial design.

The real battleground is not whether the lead asset is active, but whether the market is discounting too much of the pipeline optionality into one “platform” narrative. If Phase 2b lupus data are merely decent rather than clearly differentiated, the multiple expansion thesis can stall despite a successful psoriasis filing path, because investors will start haircutting the probability of follow-on indications and peak sales breadth. Conversely, a clean lupus signal would extend duration on the story and push the valuation from single-asset biotech toward a more durable multi-indication franchise, which is what long-only capital typically pays for.

Near term, the key risk is that the name has already done a lot of the work over the past year, so the bar is likely set at “beat-and-raise” rather than “continue execution.” With a large cash runway, financing overhang is muted, which removes one traditional bear case and shifts the debate to clinical execution and commercial credibility. That means the stock is vulnerable to a sharp de-rating on even modest disappointment, because there is less balance-sheet stress to force a lower entry point.

Key Decisions for Investors

• Tactically long ALMS into the next data catalyst window only on weakness, not strength; use a 4-8 week horizon and size assuming a 20-30% downside gap if lupus data underwhelm.
• For event-driven upside, buy ALMS call spreads dated just beyond the expected Q3 lupus readout; prefer defined-risk structures because the stock has already re-rated materially and implied expectations are likely elevated.
• If already long ALMS, trim into pre-data momentum and keep a residual core position for the NDA filing catalyst; the best risk/reward is likely before the next binary event, not after it.
• Consider a biotech pair: long ALMS / short a higher-duration, preclinical autoimmune name to isolate late-stage clinical optionality from broader sector beta.
• Avoid chasing the stock after a strong run unless the next leg is accompanied by volume and upward estimate revisions; absent that, the setup is vulnerable to sell-the-news behavior.